AG-270

first-in-class oral MAT2A allosteric inhibitor

synthetic lethal candidate in Ph. I for MTAP-

from >2000 fragment library and SBDD

J. Med. Chem., Apr. 8, 2021

Agios Pharmaceuticals, Cambridge, MA

The Agios first-in-class oral MAT2A enzyme allosteric inhibitor, AG-270, is a Ph. I clinical candidate for tumors with MTAP gene loss. The inhibitor works on a synthetic lethality principle: the MTAP-loss which drives…


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks